focus -WSS

focus

author：explore 2025-10-02 14:22:47 - browse：17

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Why did Pfizer dish out millions for a Super Bowl ad?

WSS

AI can decode, harness the power of the humane immune system

Was Amgen transparent enough on FDA's concern on cancer drug?

Sana to lay off nearly a third of staff, de

'Revelatory' study finds a smoking impact that remains after quitting

PhRMA lawsuit over Medicare drug price negotiation tossed

When women are denied an abortion, their children fare worse than peers

focus

focus

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bill would stop addiction treatment from triggering child abuse inquiry

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Biden report: The neurospychology of memory and aging

What does generative AI mean for health care? We asked experts

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medicare details structure of new drug price negotiation program

Medical mystery: When a cough is not just a cough

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AI can decode, harness the power of the humane immune system

hotspot

Vaccine advisory panel ACIP left half staffed by HHS

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medical mystery: When a cough is not just a cough

Medicare threatens to cut off funding for HCA's Mission hospital

Gilead might be held responsible for not developing a drug

To avoid data mishandling cases, universities eye AI and other tools

focus

focus

explore

explore